Expanding Development of High-Risk Virus Therapies Using Memory T Cell Platform

Lucas Bio, a cell therapy development company under the Boryung Group, is partnering with the Korea Pasteur Institute to develop a memory T cell therapy for Severe Fever with Thrombocytopenia Syndrome (SFTS).


Lucas Bio, Korea Pasteur Institute corporate logo image. Boryeong

Lucas Bio, Korea Pasteur Institute corporate logo image. Boryeong

View original image

On July 3, the two organizations announced that they have signed an agreement to jointly develop an antigen-specific memory T cell therapy candidate targeting SFTS. Through this collaboration, they plan to jointly identify therapeutic candidates and conduct preclinical efficacy evaluations, accelerating the establishment of a foundation for clinical entry.


SFTS is a tick-borne infectious disease classified as a high-risk viral infection, with both patients and fatalities reported annually in Korea. As there are currently no approved vaccines or treatments, there is a significant unmet medical need for this disease.


The Korea Pasteur Institute will be responsible for the preclinical evaluation and viral analysis of the SFTS therapy candidate. Lucas Bio will utilize its proprietary memory T cell platform technology to develop antigen-specific T cells and plans to pursue clinical entry in the future.


Lucas Bio has previously expanded the scope of its platform application based on its experience in developing multi-virus T cell therapies. With this collaboration, both organizations aim to strengthen their capabilities in developing therapies for high-risk infectious diseases and plan to expand research to a broader range of viral infections.


Jang Seungki, Director of the Korea Pasteur Institute, stated, "This joint research presents new possibilities for immune therapeutic strategies that directly target high-risk virus-infected cells. We will continue to collaborate to offer a new paradigm in the development of therapeutics for infectious diseases."



Jo Seokgu, CEO of Lucas Bio, said, "By establishing a DTK-based healthy donor memory T cell banking system, we aim to develop it into a national platform for responding to infectious diseases."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing